Neurocrine Biosciences - NBIX Stock Forecast, Price & News

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX traded up $0.75 on Friday, hitting $105.63. The company had a trading volume of 1,233,794 shares, compared to its average volume of 746,506. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of 960.36 and a beta of 0.58. The company has a current ratio of 3.57, a quick ratio of 3.47 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average of $96.56 and a two-hundred day moving average of $91.76. Neurocrine Biosciences has a 52 week low of $71.88 and a 52 week high of $109.26.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays lifted their target price on shares of Neurocrine Biosciences from $110.00 to $113.00 and gave the company an "overweight" rating in a research note on Friday, August 5th. Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $100.00 to $102.00 and gave the company an "equal weight" rating in a research note on Friday, July 15th. Robert W. Baird lifted their target price on shares of Neurocrine Biosciences from $117.00 to $125.00 in a research note on Friday, August 5th. Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Thursday, April 28th. Finally, StockNews.com upgraded shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research note on Monday, August 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $113.60.

Insider Activity

In related news, insider Julie Cooke sold 754 shares of the firm's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $100.00, for a total transaction of $75,400.00. Following the transaction, the insider now directly owns 16,918 shares of the company's stock, valued at $1,691,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.40% of the company's stock.